Davita Inc. (NYSE: DVA) has reported its financial and operating results for the quarter and year ended December 31, 2025. The company's consolidated revenues for the period were $3.620 billion for the quarter and $13.643 billion for the year. The operating income was $561 million for the quarter and $2,044 million for the year, with adjusted operating income at $586 million for the quarter and $2,094 million for the year.
Diluted earnings per share from continuing operations were reported at $2.94 for the quarter and $9.51 for the year, with adjusted diluted earnings per share from continuing operations at $3.40 for the quarter and $10.78 for the year.
Operating cash flow stood at $541 million for the quarter and $1,887 million for the year, with free cash flow at $309 million for the quarter and $1,024 million for the year.
The company also reported repurchasing 2.7 million shares of its common stock at an average price paid of $122.78 per share in the quarter and 12.7 million shares at an average price paid of $140.09 per share for the year.
In terms of dialysis metrics, the total U.S. dialysis treatments for the fourth quarter of 2025 were 7,264,520, representing a per day decrease of (0.1)% compared to the third quarter of 2025. Normalized non-acquired treatment growth in the fourth quarter of 2025 compared to the fourth quarter of 2024 was (0.6)%.
The company's effective income tax rate on income from continuing operations was reported at 20.0% for the quarter and 21.8% for the year.
As of December 31, 2025, Davita provided dialysis services to a total of approximately 295,000 patients at 3,242 outpatient dialysis centers, of which 2,657 centers were located in the United States and 585 centers were located in 14 countries outside of the United States.
Looking ahead, Davita has provided its 2026 guidance, with adjusted operating income expected to range from $2,085 million to $2,235 million, adjusted diluted net income from continuing operations per share attributable to Davita Inc. expected to range from $13.60 to $15.00, and free cash flow expected to range from $1,000 million to $1,250 million.
The market has reacted to these announcements by moving the company's shares -1.04% to a price of $104.74. If you want to know more, read the company's complete 8-K report here.
